EUVIMEDEUVIMED entdecken
Crossref

Pyeongwi‐San, a Traditional Digestant, Mitigates Proton Pump Inhibitor‐Induced Dyspepsia Through Gut Microbial and Cholinergic Mechanisms in Mice

Jing-Hua Wang iD, Song-Yi Han iD, Kyung Jae Lee, Mi Young Lim iD, Hojun Kim iD

Neurogastroenterology & Motility · 2026-11 · 38 (11)

DOI: 10.1111/nmo.70482 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurogastroenterology & Motility, online erschienen am 04.11.2026. Verfasst von Jing-Hua Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Oriental Medicine, Dongguk University, Goyang, Republic of Korea. Hauptthemen laut MEDLINE: Proton Pump Inhibitors, Gastrointestinal Microbiome, Drugs, Chinese Herbal, Dyspepsia. Die Arbeit nennt 45 Literaturangaben. Gefördert von: National Research Foundation, Korea Food Research Institute, Dongguk University Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Long‐term use of proton pump inhibitors (PPIs) is frequently associated with gastrointestinal (GI) side effects, including dyspepsia, mediated through alterations in gastric pH, impaired GI motility, and gut microbiota dysbiosis. Traditional East Asian herbal formulas—Pyeongwi‐san (PS), Yijung‐tang (YT), and Shihosogan‐tang (ST)—have long been employed clinically for GI disorders; however, their comparative efficacy and mechanistic profiles in PPI‐induced GI dysfunction remain undefined.

Purpose

This study aimed to compare the therapeutic efficacy and underlying mechanisms of PS, YT, and ST in a murine model of PPI‐induced GI dysfunction, with particular focus on motility, mucosal integrity, gut microbiota modulation, and relevant biomarker responses.

Methods

Male C57BL/6 mice received oral esomeprazole (160 mg/kg/day) for 4 weeks to induce dyspeptic symptoms. Concurrently, animals were administered PS, YT, or ST (1 g/kg/day), or mosapride (3 mg/kg/day) as a positive control. Outcome measures included gastric acid secretion, intragastric pH, GI motility (gastric emptying and intestinal transit), mucosal histopathology, serum and intestinal hormone levels (secretin, acetylcholine), fecal short‐chain fatty acid (butyrate) concentrations, gut microbiota composition (diversity indices and taxonomic profiling), mucosal barrier gene expression (MUC2, ZO‐1, Occludin), proinflammatory cytokines (IL‐1β, TNF‐α), and H + /K + ‐ATPase protein expression.

Results

Esomeprazole reliably suppressed gastric acid secretion, elevated intragastric pH, impaired GI motility, induced mucosal injury, and caused gut microbiota dysbiosis. Among the three herbal formulas tested, PS showed significant improvements across a broader range of measured endpoints relative to the PPI group. PS significantly improved gastric emptying and intestinal transit times ( p < 0.05 vs. PPI group), whereas mosapride improved gastric emptying but showed no significant effect on intestinal transit. It further elevated serum secretin, intestinal acetylcholine, and fecal butyrate levels ( p < 0.05 vs. PPI group); restored gut microbiota alpha‐diversity; and upregulated mucosal barrier genes. PS also suppressed proinflammatory cytokine expression and modulated H + /K + ‐ATPase protein expression, indicative of integrated gastroprotective and prokinetic mechanisms. YT and ST also showed significant effects on selected endpoints.

Conclusion

PS most effectively attenuated PPI‐induced GI dysfunction through a multi‐target mechanism encompassing prokinetic activity, gut microbiota restoration, mucosal barrier reinforcement, and immunomodulatory regulation of key hormones and cytokines. These findings position PS as a promising botanical candidate for the management of PPI‐related dyspepsia, warranting further investigation in controlled clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proton Pump InhibitorsGastrointestinal MicrobiomeDrugs, Chinese HerbalDyspepsiaAnimalsMaleMiceMice, Inbred C57BLGastrointestinal Motility

Stichwörter der Autor:innen

acetylcholinebutyratedyspepsiagastrointestinal motilitygut microbiotaherbal formulaproton pump inhibitorsecretin

Substanzen

Proton Pump InhibitorsDrugs, Chinese Herbal

Autor:innen und Institutionen

  • Institute of Oriental Medicine, Dongguk University, Goyang, Republic of Korea.
  • Department of Rehabilitation Medicine of Korean Medicine, Dongguk University, Goyang-si, Republic of Korea.
  • College of Korean Medicine, Dongguk University, Goyang-si, Republic of Korea.
  • Personalized Diet Research Group, Korea Food Research Institute, Wanju-gun, Jeollabuk-do, Republic of Korea.

ORCID-Profile: Jing-Hua Wang, Song-Yi Han, Mi Young Lim, Hojun Kim

Förderung

  • National Research Foundation
  • Korea Food Research Institute
  • Dongguk University Research Fund

Zitieren

APA

Wang, J. H., Han, S. Y., Lee, K. J., Lim, M. Y., & Kim, H. (2026). Pyeongwi‐San, a Traditional Digestant, Mitigates Proton Pump Inhibitor‐Induced Dyspepsia Through Gut Microbial and Cholinergic Mechanisms in Mice. Neurogastroenterology & Motility, 38(11). https://doi.org/10.1111/nmo.70482

Vancouver

Wang JH, Han SY, Lee KJ, Lim MY, Kim H. Pyeongwi‐San, a Traditional Digestant, Mitigates Proton Pump Inhibitor‐Induced Dyspepsia Through Gut Microbial and Cholinergic Mechanisms in Mice. Neurogastroenterology & Motility. 2026;38(11). doi:10.1111/nmo.70482

BibTeX
@article{Wang2026,
  author = {Wang, Jing-Hua and Han, Song-Yi and Lee, Kyung Jae and Lim, Mi Young and Kim, Hojun},
  title = {Pyeongwi‐San, a Traditional Digestant, Mitigates Proton Pump Inhibitor‐Induced Dyspepsia Through Gut Microbial and Cholinergic Mechanisms in Mice},
  journal = {Neurogastroenterology & Motility},
  year = {2026},
  volume = {38},
  number = {11},
  doi = {10.1111/nmo.70482}
}
Kostenlos starten →